Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 16.21
KMDA's Cash-to-Debt is ranked lower than
54% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. KMDA: 16.21 )
Ranked among companies with meaningful Cash-to-Debt only.
KMDA' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.32  Med: 6.93 Max: N/A
Current: 16.21
Equity-to-Asset 0.68
KMDA's Equity-to-Asset is ranked higher than
51% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. KMDA: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
KMDA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.66 Max: 0.73
Current: 0.68
0.28
0.73
Piotroski F-Score: 3
Altman Z-Score: 4.57
Beneish M-Score: -1.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -9.70
KMDA's Operating Margin % is ranked higher than
67% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. KMDA: -9.70 )
Ranked among companies with meaningful Operating Margin % only.
KMDA' s Operating Margin % Range Over the Past 10 Years
Min: -121.42  Med: -16.25 Max: 5.83
Current: -9.7
-121.42
5.83
Net Margin % -11.31
KMDA's Net Margin % is ranked higher than
67% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. KMDA: -11.31 )
Ranked among companies with meaningful Net Margin % only.
KMDA' s Net Margin % Range Over the Past 10 Years
Min: -170.4  Med: -17.36 Max: 0.63
Current: -11.31
-170.4
0.63
ROE % -12.41
KMDA's ROE % is ranked higher than
68% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. KMDA: -12.41 )
Ranked among companies with meaningful ROE % only.
KMDA' s ROE % Range Over the Past 10 Years
Min: -196.88  Med: -14.74 Max: 1.02
Current: -12.41
-196.88
1.02
ROA % -8.54
KMDA's ROA % is ranked higher than
70% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. KMDA: -8.54 )
Ranked among companies with meaningful ROA % only.
KMDA' s ROA % Range Over the Past 10 Years
Min: -59.18  Med: -10.19 Max: 0.39
Current: -8.54
-59.18
0.39
ROC (Joel Greenblatt) % -15.16
KMDA's ROC (Joel Greenblatt) % is ranked higher than
73% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. KMDA: -15.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KMDA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -179.58  Med: -22.36 Max: 15.92
Current: -15.16
-179.58
15.92
3-Year Revenue Growth Rate -0.70
KMDA's 3-Year Revenue Growth Rate is ranked lower than
57% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. KMDA: -0.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
KMDA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.7  Med: 4.6 Max: 50.5
Current: -0.7
-8.7
50.5
GuruFocus has detected 5 Warning Signs with Kamada Ltd $KMDA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KMDA's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

KMDA Guru Trades in Q2 2016

Jim Simons 172,800 sh (+1.47%)
John Paulson 736,117 sh (unchged)
» More
Q3 2016

KMDA Guru Trades in Q3 2016

Jim Simons 188,500 sh (+9.09%)
John Paulson 730,800 sh (-0.72%)
» More
Q4 2016

KMDA Guru Trades in Q4 2016

Jim Simons 227,000 sh (+20.42%)
John Paulson 730,800 sh (unchged)
» More
Q1 2017

KMDA Guru Trades in Q1 2017

Jim Simons 264,800 sh (+16.65%)
John Paulson 730,800 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KMDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:OBSV, NAS:CGEN, OTCPK:CKPT, NAS:PETX, NAS:SELB, OTCPK:CLVLF, OTCPK:SIGA, NAS:CRIS, OTCPK:TYMI, NAS:CERS, NAS:AVXL, NAS:VYGR, NAS:IDRA, AMEX:MTNB, NAS:VCYT, NAS:XBIT, NAS:DVAX, NAS:NVAX, NAS:CRVS, NAS:ABEO » details
Traded in other countries:K3M.Germany, KMDA.Israel,
Headquarter Location:Israel
Kamada Ltd is an orphan drug, plasma-derived protein therapeutics company and develops & produces specialty plasma-derived protein therapeutics. Its flagship product include Glassia.

Kamada Ltd. develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises of Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other. Its business is segmented into two - Proprietary Product and Distribution. The Proprietary Product segment develops and manufactures plasma-derived therapeutics and market them in more than 15 countries. The Distribution segment distributes drugs manufactured by third-parties for critical use in Israel, produced from plasma or its derivative products.

Top Ranked Articles about Kamada Ltd

Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference
Kamada to Host First Quarter 2017 Financial Results Conference Call on May 16
Kamada to Host R&D Day Focused on Graft versus Host Disease (GvHD)

NESS ZIONA, Israel, March 02, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, will host a Research and Development Day to highlight Graft versus Host Disease (GvHD) in New York City on March 3 from 12:00pm to 1:30pm Eastern Time.
The meeting will feature a presentation by key opinion leaders H. Joachim Deeg, MD (Fred Hutchinson Cancer Research Center) and David M. Gelmont, MD (formerly at Shire/Baxalta), who will discuss the current treatment landscape for GvHD in bone marrow transplant patients and the unmet medical need for patients who develop acute GvHD. Both KOLs will be available to answer questions following the lunch. Kamada management will provide an overview of the Company’s ongoing clinical development work with their liquid form of Alpha-1 Antitrypsin (AAT) to treat acute Graft versus Host Disease, including published data to-date, and the company's clinical strategy moving forward. Dr. Joachim Deeg is a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center and a Professor in the Division of Medical Oncology at University of Washington School of Medicine.  Dr. Deeg treats patients with bone marrow failure such as aplastic anemia and bone cancers, such as myelodysplastic syndrome, leukemia, and myelofibrosis. His clinical expertise is in treating hematologic malignancies, hematopoietic stem cell transplantation, graft-versus-host-disease, and iron overload. Dr. Deeg is also actively involved in research studying inflammatory responses and GvHD, separation of GvHD and GVL effects by AAT, and the pathophysiology of MDS. He has published extensively on the use of hematopoietic cell transplantation in blood cancer patients. Dr. David Gelmont has over 16 years’ experience in the pharmaceutical industry, conducting and supervising clinical trials in several areas including: neurology, Alzheimer’s disease, immune deficiency, complement biology, autoimmune diseases, GvHD, coagulopathy, sepsis and emphysema.  Most recently he was a Senior Medical Director for Baxalta and Shire, and clinical advisor for Kamada's GvHD program.   He has hands-on experience with clinical trials ranging from phase-1 through phase-4 as well as PASS and registry type of trials. Additionally, Dr. Gelmont was in charge of submission of multiple INDs and BLAs and represented sponsors in meetings with regulatory agencies including US FDA, EMA, Paul Ehrlich Institute, the Dutch (CCMO), the French (AFSSAPS) competent authorities, and several other ministries of health. Dr. Gelmont’s academic career spanned over 18 years and included managing ICUs, Step-Down units, fellowship programs; he trained nearly 150 fellows in pulmonary and critical care medicine. This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only.  Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please reply to this email or contact LifeSci Advisors, LLC at [email protected].  A live and archived webcast of the event, with slides, will be available at http://lifesci.rampard.com/20170303/reg.jsp and on the Investors section of the Company’s website at www.kamada.com. About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.  AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is GLASSIA®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors.  In addition to GLASSIA®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency for which a MAA was submitted to the EMA after completing a pivotal Phase 2/3 clinical trials in Europe.  Kamada has also completed its Phase 2 clinical trials in the U.S for the treatment of AAT deficiency with inhaled AAT. In addition, Kamada's intravenous AAT is in development for other indications such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties. Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA submissions and authorizations.  Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions.  Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays.  The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
CONTACTS:
Gil Efron
Chief Financial Officer
[email protected]

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]

Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 175.44
KMDA's Forward PE Ratio is ranked lower than
99.99% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. KMDA: 175.44 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 4.04
KMDA's PB Ratio is ranked higher than
50% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. KMDA: 4.04 )
Ranked among companies with meaningful PB Ratio only.
KMDA' s PB Ratio Range Over the Past 10 Years
Min: 1.59  Med: 3.11 Max: 13.4
Current: 4.04
1.59
13.4
PS Ratio 3.70
KMDA's PS Ratio is ranked higher than
79% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. KMDA: 3.70 )
Ranked among companies with meaningful PS Ratio only.
KMDA' s PS Ratio Range Over the Past 10 Years
Min: 1.84  Med: 3.55 Max: 16.46
Current: 3.7
1.84
16.46
EV-to-EBIT -33.86
KMDA's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. KMDA: -33.86 )
Ranked among companies with meaningful EV-to-EBIT only.
KMDA' s EV-to-EBIT Range Over the Past 10 Years
Min: -80.6  Med: -9.7 Max: 1542
Current: -33.86
-80.6
1542
EV-to-EBITDA -71.06
KMDA's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. KMDA: -71.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
KMDA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -218.2  Med: -12.1 Max: 199.4
Current: -71.06
-218.2
199.4
Current Ratio 2.82
KMDA's Current Ratio is ranked lower than
64% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. KMDA: 2.82 )
Ranked among companies with meaningful Current Ratio only.
KMDA' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 3.19 Max: 4.42
Current: 2.82
2.21
4.42
Quick Ratio 1.71
KMDA's Quick Ratio is ranked lower than
71% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. KMDA: 1.71 )
Ranked among companies with meaningful Quick Ratio only.
KMDA' s Quick Ratio Range Over the Past 10 Years
Min: 1.45  Med: 2.3 Max: 3.59
Current: 1.71
1.45
3.59
Days Inventory 187.06
KMDA's Days Inventory is ranked lower than
67% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. KMDA: 187.06 )
Ranked among companies with meaningful Days Inventory only.
KMDA' s Days Inventory Range Over the Past 10 Years
Min: 97.6  Med: 154.27 Max: 187.18
Current: 187.06
97.6
187.18
Days Sales Outstanding 67.65
KMDA's Days Sales Outstanding is ranked lower than
69% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. KMDA: 67.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
KMDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.68  Med: 92.42 Max: 135.5
Current: 67.65
48.68
135.5
Days Payable 128.94
KMDA's Days Payable is ranked higher than
67% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. KMDA: 128.94 )
Ranked among companies with meaningful Days Payable only.
KMDA' s Days Payable Range Over the Past 10 Years
Min: 89.24  Med: 114.18 Max: 144.44
Current: 128.94
89.24
144.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.40
KMDA's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. KMDA: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KMDA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -33.2  Med: -9.3 Max: -0.4
Current: -0.4
-33.2
-0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 6.33
KMDA's Price-to-Net-Current-Asset-Value is ranked higher than
53% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. KMDA: 6.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KMDA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.49  Med: 4.13 Max: 43.45
Current: 6.33
2.49
43.45
Price-to-Tangible-Book 4.04
KMDA's Price-to-Tangible-Book is ranked higher than
56% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. KMDA: 4.04 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KMDA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.81  Med: 3.01 Max: 12.15
Current: 4.04
1.81
12.15
Price-to-Intrinsic-Value-Projected-FCF 0.11
KMDA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. KMDA: 0.11 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
KMDA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.11  Med: 0.11 Max: 0.11
Current: 0.11
Price-to-Median-PS-Value 1.04
KMDA's Price-to-Median-PS-Value is ranked lower than
58% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. KMDA: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
KMDA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 0.94 Max: 4.63
Current: 1.04
0.56
4.63
Earnings Yield (Greenblatt) % -2.95
KMDA's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. KMDA: -2.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KMDA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.95  Med: 0.8 Max: 1.8
Current: -2.95
-2.95
1.8

More Statistics

Revenue (TTM) (Mil) $74.35
EPS (TTM) $ -0.22
Beta1.08
Short Percentage of Float0.03%
52-Week Range $3.60 - 7.34
Shares Outstanding (Mil)36.45

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 101 134 193
EPS ($) 0.04 0.21 0.64
EPS without NRI ($) 0.04 0.21 0.64
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)